BEVERLY, Mass. and TORONTO, Aug. 22, 2017 -- Hamilton Thorne Ltd. (TSX-V:HTL) today announced a delay in the release of its financial results for the three and six months ended June 30, 2017 and related conference call in order to allow additional time to conclude the accounting for the period. The Company will announce the timing of the rescheduled conference in a press release concurrent with the release of financial results, which will be delivered within the requisite period. The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.com and on www.sedar.com.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact: David Wolf, President & CEO Hamilton Thorne Ltd. 978-921-2050 ir@hamiltonthorne.com Michael Bruns, CFO Hamilton Thorne Ltd. 978-921-2050 ir@hamiltonthorne.com
